This surge of interest began with the discovery that the Cytotoxic T-lymphocyte Antigen (CTLA-4) blocking antibody, ipilimumab, improved overall survival in patients with metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.